Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Message from Christina at ATE to one of the other investors

<< Previous

Bullboard Posts

Next >>

Post by Straylighton Feb 11, 2021 11:14am

274 Views

Post# 32537792

Message from Christina at ATE to one of the other investors

Pulled this from another board. Poster named Ogi reached out to Christina Cameron at ATE with a question about the deal. This was her response:

Hi ..., Thank you for your interest. The timing is immediate. We receive the US$20m upfront immediately. Nuance will run their own phase 3 trial in china at their expense. Separately, Antibe will continue Phase 3 development through FDA and seek additional partners for the other markets. Please let me know if you have any further questions. Many thanks, Christina

<< Previous

Bullboard Posts

Next >>

Global Tungsten Market and Supply Security